Insulin

Pharmaceutical Biotechnology: Fundamentals and Applications, Fourth Edition

Volumn , Issue , 2013, Pages 255-275

  Beals, John M ^a   Defelippis, Michael R ^a   Kovach, Paul M ^a   Jackson, Jeffrey A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL STABILITY; DNA; DRUG PRODUCTS; GENETIC ENGINEERING; ION EXCHANGE; PROTEINS; PURIFICATION;

CHROMATOGRAPHIC PROCESS; EXOGENOUS SOURCE; FORMULATION DEVELOPMENT; GLUCOSE CONTROL; MANUFACTURING PROCESS; MOLECULAR PROPERTIES; PROCESSING CONDITION; SECRETION PROFILES;

INSULIN;

EID: 84956701595     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-6486-0_12     Document Type: Chapter

References (107)

1. Anderson JH Jr, Brunelle RL, Keohane P, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R (1997) Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. Arch Intern Med 157: 1249-1255
2. Baker EN, Blundell TL, Cutfield JF, Cutfield SM, Dodson EJ, Dodson GG, Hodgkin DM, Hubbard RE, Isaacs NW, Reynolds CD, Sakabe K, Sakabe N, Vijayan NM (1988) The structure of 2Zn pig insulin crystals at 1. 5Å resolution. Philos Trans R Soc Lond B Biol Sci 319: 369-456
3. Balschmidt P (1996) Asp B28 Insulin crystals. US Patent 5, 547, 930
4. Bell DS, Clements RS Jr, Perentesis G, Roddam R, Wagenknecht L (1991) Dosage accuracy of self-mixed vs premixed insulin. Arch Intern Med 151: 2265-2269
5. Binder C (1969) Absorption of injected insulin. A clinicalpharmacologic study. Acta Pharmacol Toxicol (Copenh) 27(Suppl 2): 1-84
6. Binder C, Lauritzen T, Faber O, Pramming S (1984) Insulin pharmacokinetics. Diabetes Care 7: 188-199
7. Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF (2011) Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care 34: 661-665
8. Bliss M (1982) Who discovered insulin. In: The discovery of insulin. McClelland and Stewart Limited, Toronto, pp 189-211
9. Boldo A, Comi RJ (2012) Clinical experience with U500 insulin: risks and benefits. Endocr Pract 18: 56-61
10. Brackenridge B (1994) Diabetes medicines: insulin. In: Brackenridge B (ed) Managing your diabetes. Eli Lilly and Company, Indianapolis, pp 36-50
11. Brader ML, Dunn MF (1991) Insulin hexamers: new conformations and applications. Trends Biochem Sci 16: 341-345
12. Brange J (1987a) Insulin preparations. In: Galenics of insulin. Springer, Berlin, pp 17-39
13. Brange J (1987b) Production of bovine and porcine insulin. In: Galenics of insulin, Springer, Berlin, pp 1-5
14. Brange J (1987c) Insulin preparations. In: Galenics of insulin. Springer, Berlin, pp 58-60
15. Brange J, Langkjaer L (1992) Chemical stability of insulin. 3. Influence of excipients, formulation, and pH. Acta Pharm Nord 4: 149-158
16. Brange J, Ribel U, Hansen JF, Dodson G, Hansen MT, Havelund S, Melberg SG, Norris F, Norris K, Snel L et al (1988) Monomeric insulins obtained by protein engineering and their medical implications. Nature 333: 679-682
17. Brange J, Owens DR, Kang S, Vølund A (1990) Monomeric insulins and their experimental and clinical applications. Diabetes Care 13: 923-954
18. Brange J, Havelund S, Hougaard P (1992a) Chemical stability of insulin. 2. Formation of higher molecular weight transformation products during storage of pharmaceutical preparations. Pharm Res 9: 727-734
19. Brange J, Langkjaer L, Havelund S, Vølund A (1992b) Chemical stability of insulin. 1. Hydrolytic degradation during storage of pharmaceutical preparations. Pharm Res 9: 715-726
20. Brems DN, Alter LA, Beckage MJ, Chance RE, DiMarchi RD, Green LK, Long HB, Pekar AH, Shields JE, Frank BH (1992) Altering the association properties of insulin by amino acid replacement. Protein Eng 6: 527-533
21. Brennan TV, Clarke S (1994) Deamidation and isoasparate formation in model synthetic peptides. In: Aswad DW (ed) Deamidation and isoaspartate formation in peptides and proteins. CRC Press, Boca Raton, pp 65-90
22. Cefalu WT (2004) Concept, strategies, and feasibility of noninvasive insulin delivery. Diabetes Care 27: 239-246
23. Cernea S, Kidron M, Wohlgelernter J, Modi P, Raz I (2004) Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique. Clin Ther 26: 2084-2091
24. Chacra AR, Kipnes M, Ilag LL, Sarwat S, Giaconia J, Chan J (2010) Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with type 1 diabetes. Diabet Med 27: 563-569
25. Charman SA, McLennan DN, Edwards GA, Porter CJH (2001) Lymphatic absorption is a significant contributor to the subcutaneous bioavailability of insulin in a sheep model. Pharm Res 18: 1620-1626
26. Charvet R, Soula G, Mora G, Soula O, Soula R (2010) Fast-acting insulin formulations, US Patent Application 2010249020A
27. Ciszak E, Beals JM, Frank BH, Baker JC, Carter ND, Smith GD (1995) Role of the C-terminal B-chain residues in insulin assembly: the structure of hexameric LysB28ProB29-human insulin. Structure 3: 615-622
28. Dailey G, Rosenstock J, Moses RG, Ways K (2004) Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 27: 2363-2368
29. Darrington RT, Anderson BD (1995) Effects of insulin concentration and self-association on the partitioning of its A-21 cyclic anhydride intermediate to desamido insulin and covalent dimer. Pharm Res 12: 1077-1084
30. Davis SN, Thompson CJ, Brown MD, Home PD, Alberti KG (1991) A comparison of the pharmacokinetics and metabolic effects of human regular and NPH mixtures. Diabetes Res Clin Pract 13: 107-117
31. De la Peña A, Riddle M, Morrow LA, Jiang HH, Linnebjerg H, Scott A, Win KM, Hompesch M, Mace KF, Jacobson JG, Jackson JA (2011) Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care 34: 2496-2501
32. Deckert T (1980) Intermediate-acting insulin preparations: NPH and lente. Diabetes Care 3: 623-626
33. DeFelippis MR, Bakaysa DL, Bell MA, Heady MA, Li S, Pye S, Youngman KM, Radziuk J, Frank BH (1998) Preparation and characterization of a cocrystalline suspension of [LysB28, ProB29]-human insulin analogue. J Pharm Sci 87: 170-176
34. DeFelippis MR, Bell MA, Heyob JA, Storms SM (2006) In vitro stability of insulin lispro in continuous subcutaneous insulin infusion. Diabetes Technol Ther 8: 358-368
35. Derewenda U, Derewenda Z, Dodson EJ, Dodson GG, Reynolds CD, Smith GD, Sparks C, Swenson D (1989) Phenol stabilizes more helix in a new symmetrical zinc insulin hexamer. Nature 338: 594-596
36. Dodd SW, Havel HA, Kovach PM, Lakshminarayan C, Redmon MP, Sargeant CM, Sullivan GR, Beals JM (1995) Reversible adsorption of soluble hexameric insulin onto the surface of insulin crystals cocrystallized with protamine: an electrostatic interaction. Pharm Res 12: 60-68
37. Dreyer M, Prager R, Robinson A, Busch K, Ellis G, Souhami E, Van Leendert R (2005) Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 37: 702-707
38. Eljamal M, Patton JS, Foster LC, Platz RM (2003) Powdered Pharmaceutical Formulation Having Improved Dispersibility, US Patent 6, 582, 729
39. Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober SJ (2010) A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with type 2 diabetes. Diabet Med 27: 181-188
40. Galloway JA (1988) Chemistry and clinical use of insulin. In: Galloway JA, Potvin JH, Shuman CR (eds) Diabetes mellitus, 9th edn. Lilly Research Laboratories, Indianapolis, pp 105-133
41. Galloway JA, Chance RE (1994) Improving insulin therapy: achievements and challenges. Horm Metab Res 26: 591-598
42. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL (1981) Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 4: 366-376
43. Galloway JA, Spradlin CT, Jackson RL, Otto DC, Bechtel LD (1982) Mixtures of intermediate-acting insulin (NPH and Lente) with regular insulin: an update. In: Skyler JS (ed) Insulin update: 1982. Exerpta Medica, Princeton, pp 111-119
44. Garg SK, Kelly WC (2009) Insulin delivery via lungs-is it still possible? Diabetes Technol Ther 11 (Suppl 2): S1-S3
45. Gibney MA, Arce CH, Byron KJ, Hirsch LJ (2010) Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Curr Med Res Opin 26: 1519-1530
46. Goldman J, Carpenter FH (1974) Zinc binding, circular dichroism, and equilibrium sedimentation studies on insulin (bovine) and several of its derivatives. Biochemistry 13: 4566-4574
47. Hagedorn HC, Jensen BN, Krarup NB, Wodstrup I (1936) Protamine insulinate. JAMA 106: 177-180
48. Hamaguchi T, Hashimoto Y, Miyata T, Kishikawa H, Yano T, Fukushima H, Shichiri M (1990) Effect of mixing short and intermediate NPH insulin or Zn insulin suspension acting human insulin on plasma free insulin levels and action profiles. J Jpn Diabetes Soc 33: 223-229
49. Havelund S, Plum A, Ribel U, Jonassen I, Vølund A, Markussen J, Kurtzhals P (2004) The mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. Pharm Res 21: 1498-1504
50. Heinemann L (2012) New ways of insulin delivery. Int J Clin Pract 66(Suppl 175): 35-39
51. Heinemann L, Weyer C, Rave K, Stiefelhagen O, Rauhaus M, Heise T (1997) Comparison of the time-action profiles of U40-and U100-regular human insulin and the rapidacting insulin analogue B28 Asp. Exp Clin Endocrinol Diabetes 105: 140-144
52. Heinemann L, Sinha K, Weyer C, Loftager M, Hirschberger S, Heise T (1999) Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med 16: 332-338
53. Heinemann L, Pfützner A, Heise T (2001) Alternative routes of administration as an approach to improve insulin therapy: update on dermal, oral, nasal and pulmonary insulin delivery. Curr Pharm Des 7: 1327-1351
54. Heinemann L, Nosek L, Flacke F, Albus K, Krasner A, Pichotta P, Heise T, Steiner S (2012) U-100, pH-neutral formulation of VIAject®: faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes Obes Metab 14: 222-227
55. Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, Woodworth J, Gudat W, Heinemann L (1998) Timeaction profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 21: 800-803
56. Heise T, Nosek L, Rønn BB, Endahl L, Heinemann L, Kapitza C, Draeger E (2004) Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 53: 1614-1620
57. Hermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M (2001) Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basalbolus therapy. Diabetes Care 24: 296-301
58. Hoffmann JA, Chance RE, Johnson MG (1990) Purification and analysis of the major components of chum salmon protamine contained in insulin formulations using high-performance liquid chromatography. Protein Expr Purif 1: 127-133
59. Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson JH (1997) Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 20: 1827-1832
60. Home PD (2012) The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab 14: 780-788
61. Hompesch M, Ocheltree SM, Wondmagegnehu ET, Morrow LA, Kollmeier AP, Campaigne BN, Jacober SJ (2009) Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. Curr Med Res Opin 25: 2679-2687
62. Howey DC, Bowsher RR, Brunelle RL, Woodworth JR (1994) [Lys(B28), Pro(B29)]-human insulin: a rapidly-absorbed analogue of human insulin. Diabetes 43: 396-402
63. Jansen R, Dzwolak W, Winter R (2005) Amyloidogenic selfassembly of insulin aggregates probed by high resolution atomic force microscopy. Biophys J 88: 1344-1353
64. Janssen MM, Casteleijn S, Devillé W, Popp-Snijders C, Roach P, Heine RJ (1997) Nighttime insulin kinetics and glycemic control in type 1 diabetic patients following administration of an intermediate-acting lispro preparation. Diabetes Care 20: 1870-1873
65. Kaarsholm NC, Havelund S, Hougaard P (1990) Ionization behavior of native and mutant insulins: pK perturbation of B13-Glu in aggregated species. Arch Biochem Biophys 283: 496-502
66. Krayenbuhl C, Rosenberg T (1946) Crystalline protamine insulin. Rep Steno Hosp (Kbh) 1: 60-73
67. Kroeff EP, Owen RA, Campbell EL, Johnson RD, Marks HI (1989) Production scale purification of biosynthetic human insulin by reversed-phase high-performance liquid chromatography. J Chromatogr 461: 45-61
68. Kurtz AB, Gray RS, Markanday S, Nabarro JD (1983) Circulating IgG antibody to protamine in patients treated with protamine-insulins. Diabetologia 25: 322-324
69. Lane WS, Cochran EK, Jackson JA, Scism-Bacon JL, Corey IB, Hirsch IB, Skyler JS (2009) High-dose insulin therapy: is it time for U-500 insulin? Endocr Pract 15: 71-79
70. Modi P, Mihic M, Lewin A (2002) The evolving role of oral insulin in the treatment of diabetes using a novel RapidMistSystem. Diabetes Metab Res Rev 18(Suppl 1): S38-S42
71. Muchmore DB, Vaughn DE (2010) Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations. J Diabetes Sci Technol 4: 419-428
72. Nell LJ, Thomas JW (1988) Frequency and specificity of protamine antibodies in diabetic and control subjects. Diabetes 37: 172-176
73. Nielsen L, Khurana R, Coats A, Frokjaer S, Brange J, Vyas S, Uversky VN, Fink AL (2001) Effect of environmental factors on the kinetics of insulin fibril formation: elucidation of the molecular mechanism. Biochemistry 40: 6036-6046
74. Ocheltree SM, Hompesch M, Wondmagegnehu ET, Morrow L, Win K, Jacober SJ (2010) Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes. Eur J Endocrinol 163: 217-223
75. Patton JS, Bukar J, Nagarajan S (1999) Inhaled insulin. Adv Drug Deliv Rev 35: 235-247
76. Patton JS, Bukar JG, Eldon MA (2004) Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet 43: 781-801
77. Pekar AH, Frank BH (1972) Conformation of proinsulin. A comparison of insulin and proinsulin self-association at neutral pH. Biochemistry 11: 4013-4016
78. Peyrot M, Rubin RR (2010) Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. Diabetes Technol Ther 12: 49-55
79. Pfutzner A, Mann AE, Steiner SS (2002) Technosphere/insulin-a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 4: 589-594
80. Porcellati F, Bolli GB, Fanelli CG (2011) Pharmacokinetics and pharmacodynamics of basal insulins. Diabetes Technol Ther 13(Suppl 1): S15-S24
81. Porter CJ, Charman SA (2000) Lymphatic transport of proteins after subcutaneous administration. J Pharm Sci 89: 297-310
82. Richardson PC, Boss AH (2007) Technosphere insulin technology. Diabetes Technol Ther 9(Suppl 1): S65-S72
83. Robertson KE, Glazer NB, Campbell RK (2000) The latest developments in insulin injection devices. Diabetes Educ 26: 135-152
84. Schade DS, Santiago JV, Skyler JS, Rizza RA (1983) Intensive insulin therapy. Medical Examination Publishing, Princeton, p 24
85. Segal AR, Brunner JE, Burch FT, Jackson JA (2010) Use of concentrated insulin human regular (U-500) for patients with diabetes. Am J Health Syst Pharm 67: 1526-1535
86. Senstius J, Harboe E, Westermann H (2007a) In vitro stability of insulin aspart in simulated continuous subcutaneous insulin infusion using a MiniMed 508 pump. Diabetes Technol Ther 9: 75-79
87. Senstius J, Poulsen C, Hvass A (2007b) Comparison of in vitro stability for insulin aspart and insulin glulisine during simulated use in infusion pumps. Diabetes Technol Ther 9: 517-521
88. Sharrow SD, Glass LC, Dobbins MA (2012) 14-day in vitro chemical stability of insulin lispro in the MiniMed paradigm pump. Diabetes Technol Ther 14: 264-270
89. Strojek K, Shi C, Carey MA, Jacober SJ (2010) Addition of insulin lispro protamine suspension or insulin glargine to oral type 2 diabetes regimens: a randomized trial. Diabetes Obes Metab 12: 916-922
90. Supersaxo A, Hein WR, Steffen H (1990) Effect of molecular weight on the lymphatic absorption of water-soluble compounds following subcutaneous administration. Pharm Res 7: 167-169
91. USP Monographs: Insulin (2013) USP36-NF31: 3911-3913
92. Vague P, Selam JL, Skeie S, De Leeuw I, Elte JW, Haahr H, Kristensen A, Draeger E (2003) Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26: 590-596
93. Waldhäusl W, Bratusch-Marrain P, Gasic S, Kom A, Nowotny P (1979) Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man. Diabetologia 17: 221-227
94. Weyer C, Heise T, Heinemann L (1997) Insulin aspart in a 30/70 premixed formulation. Pharmacodynamic properties of a rapid-acting insulin analog in stable mixture. Diabetes Care 20: 1612-1614
95. White S, Bennett DB, Cheu S, Conley PW, Guzek DB, Gray S, Howard J, Malcolmson R, Parker JM, Roberts P, Sadrzadeh N, Schumacher JD, Seshadri S, Sluggett GW, Stevenson CL, Harper NJ (2005) EXUBERA: pharmaceutical development of a novel product for pulmonary delivery of insulin. Diabetes Technol Ther 7: 896-906
96. Whittingham JL, Edwards DJ, Antson AA, Clarkson JM, Dodson GG (1998) Interactions of phenol and m-cresol in the insulin hexamer, and their effect on the association properties of B28 pro-> Asp insulin analogues. Biochemistry 37: 11516-11523
97. Whittingham JL, Jonassen I, Havelund S, Roberts SM, Dodson EJ, Verma CS, Wilkinson AJ, Dodson GG (2004) Crystallographic and solution studies of N-lithocholyl insulin: a new generation of prolonged-acting human insulins. Biochemistry 43: 5987-5995
98. Zerhouni E (2012) Sanofi. 32nd Cowen Annual Health Care Conference, Boston. http: //en. sanofi.com/investors/events/other_events/2012/Presentation_2012-03-06_Cowen_Zerhouni. aspx. Accessed 2 Jul 2013
99. Ziesmer AE, Kelly KC, Guerra PA, George KG, Dunn KL (2012) U500 regular insulin use in insulin-resistant type 2 diabetic veteran patients. Endocr Pract 18: 34-38
100. Zinman B, Fulcher G, Rao PV, Thomas N, Endahl LA, Johansen T, Lindh R, Lewin A, Rosenstock J, Pinget M, Mathieu C (2011) Insulin degludec, an ultra-longacting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. Lancet 377: 924-931
101. American Diabetes Association (2011) Practical insulin: a handbook for prescribing providers, 3rd edn. American Diabetes Association, New York
102. Bliss M (1982) The discovery of insulin. McClelland and Stewart Limited, Toronto
103. Brange J (1987) Galenics of insulin. Springer, Berlin
104. Burant C (ed) (2008) Medical management of type 2 diabetes, 6th edn. American Diabetes Association, New York
105. Cooper T, Ainsburg A (2010) Breakthrough: Elizabeth Hughes, the discovery of insulin, and the making of a medical miracle. St. Martin's Press, New York
106. Galloway JA, Potvin JH, Shuman CR (1988) Diabetes mellitus, 9th edn. Lilly Research Laboratories, Indianapolis
107. Wolfsdorf JI (2009) Intensive diabetes management, 4th edn. American Diabetes Association, New York